Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Suven Life Sciences Ltd

SUVEN.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Biotechnology & Medical Research ·

India Small Cap Analyst: N/A

Last Close

$3.59

▲ +4.87%

Market Cap $1.01B · Vol 598.70K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.01B

Small Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

61.00

Momentum

Beta

1.59

vs Market

52W High

$3.89

7.79% below

52W Low

$1.30

171.72% above

Volume

598.70K

Avg 993.72K

P/B

5.87

Price-to-book

ROE

N/A

Return on equity

Free Float

33.42%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Suven Life Sciences Ltd (SUVEN.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SUVEN.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+7.52%

-1.68%

+65.75%

+125.94%

YTD

+105.90%

+45.56%

+354.78%

+361.61%

Financials & Valuation

TTM · Annual

Total Revenue	$761.28K
Net Income	$-29,569,117.00
Revenue Growth (YoY)	+91.02%
Gross Margin	-0.64%
Operating Margin	-4,065.42%
Net Profit Margin	-3,884.13%
ROE	N/A
ROA · ROIC	-72.78% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	421.71
P/B	5.87
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	282.56M

Technical Indicators

50-Day SMA	$3.18
200-Day SMA	$2.19
RSI (14)	61.00
Beta	1.59
52-Week High	$3.89
52-Week Low	$1.30

Volume Today	598.70K
Avg Daily Volume (30D)	993.72K
Relative Volume	0.60x
Volatility (10D)	45.12
Volatility (30D)	58.90
Free Float	33.42%

Analyst Consensus

N/A

Current Price $3.59

Mean Target N/A

52W Low$1.30 52W High$3.89

Current

Target

$1.30 $3.89

Current Analyst target

· 0 analysts

Identifiers

ExchangeNSE India

FIGIBBG001S8HXB6

ISININE495B01038

CountryIndia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Suven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Company's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (a4b2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).